Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Coronary Artery Disease V: Interprofessional Care

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...

Cholesterol: Significance and Regulation

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Risk of Recurrent Coronary Events in Patients With Familial Hypercholesterolemia; A 10-Years Prospective Study.

Frontiers in pharmacology·2021

Same author

Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia: A Global Call to Action.

JAMA cardiology·2020

Same author

Impact of age on excess risk of coronary heart disease in patients with familial hypercholesterolaemia.

Heart (British Cardiac Society)·2018

Same author

An update on familial hypercholesterolaemia.

Annals of medicine·2017

Same author

Cardiovascular disease mortality in patients with genetically verified familial hypercholesterolemia in Norway during 1992-2013.

European journal of preventive cardiology·2016

Same author

Cardiovascular disease in patients with genotyped familial hypercholesterolemia in Norway during 1994-2009, a registry study.

European journal of preventive cardiology·2016

Search research articles

Related Experiment Video

Updated: May 15, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Pitavastatin: finding its place in therapy.

Therapeutic Advances in Chronic Disease

|December 20, 2012

Summary

Pitavastatin effectively lowers LDL-C and raises HDL-C, addressing residual cardiovascular risk factors in dyslipidaemia. This well-tolerated statin offers a promising option for managing hypercholesterolemia and reducing cardiovascular risk.

Area of Science:

Cardiology
Pharmacology
Metabolic Diseases

Background:

Dyslipidaemia is a significant risk factor for cardiovascular disease.
Many patients do not achieve target low-density lipoprotein cholesterol (LDL-C) levels due to undertreatment or residual risk factors.
Non-LDL-C factors like high triglycerides and low high-density lipoprotein cholesterol (HDL-C) contribute to persistent cardiovascular risk.

Purpose of the Study:

To evaluate the efficacy and tolerability of pitavastatin in managing dyslipidaemia.
To compare pitavastatin's lipid-lowering effects with other statins.
To explore pitavastatin's potential in reducing residual cardiovascular risk.

Main Methods:

Comparative efficacy studies of pitavastatin against atorvastatin, simvastatin, and pravastatin.

Keywords:

cardiovascular dyslipidaemia hypercholesterolemia lipid pitavastatin statin

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Related Experiment Videos

Last Updated: May 15, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Assessment of lipid profiles, including LDL-C and HDL-C levels.

Evaluation of pleiotropic effects and metabolic profile of pitavastatin.

Main Results:

Pitavastatin demonstrated non-inferior or superior lipid-lowering efficacy compared to other statins.
Pitavastatin consistently produced greater and sustained increases in HDL-C levels.
The drug showed potential for reducing residual cardiovascular risk and coronary plaque regression.

Conclusions:

Pitavastatin is a well-tolerated statin with significant lipid-lowering benefits, including notable HDL-C elevation.
Its unique metabolic profile and minimal drug interactions make it suitable for patients on multiple medications.
Pitavastatin shows promise in the future management of dyslipidaemia and cardiovascular risk reduction.